- Home
- TDG vs BEATW Comparison
TDG vs BEATW Comparison
Compare TDG & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDG
- BEATW
- Stock Information
- Founded
- TDG 1993
- BEATW 2015
- Country
- TDG United States
- BEATW United States
- Employees
- TDG N/A
- BEATW 20
- Industry
- TDG Military/Government/Technical
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- TDG Industrials
- BEATW Technology
- Exchange
- TDG Nasdaq
- BEATW Nasdaq
- Market Cap
- TDG N/A
- BEATW N/A
- IPO Year
- TDG 2006
- BEATW N/A
- Fundamental
- Price
- TDG $1,383.57
- BEATW $0.51
- Analyst Decision
- TDG Buy
- BEATW
- Analyst Count
- TDG 18
- BEATW 0
- Target Price
- TDG $1,483.06
- BEATW N/A
- AVG Volume (30 Days)
- TDG 246.6K
- BEATW 4.7K
- Earning Date
- TDG 05-06-2025
- BEATW 03-14-2025
- Dividend Yield
- TDG 5.42%
- BEATW N/A
- EPS Growth
- TDG 20.43
- BEATW N/A
- EPS
- TDG 28.37
- BEATW N/A
- Revenue
- TDG $8,157,000,000.00
- BEATW N/A
- Revenue This Year
- TDG $13.05
- BEATW N/A
- Revenue Next Year
- TDG $8.65
- BEATW N/A
- P/E Ratio
- TDG $48.77
- BEATW N/A
- Revenue Growth
- TDG 16.91
- BEATW N/A
- 52 Week Low
- TDG $1,176.31
- BEATW $0.50
- 52 Week High
- TDG $1,451.32
- BEATW $0.62
- Technical
- Relative Strength Index (RSI)
- TDG 57.35
- BEATW N/A
- Support Level
- TDG $1,364.02
- BEATW N/A
- Resistance Level
- TDG $1,407.36
- BEATW N/A
- Average True Range (ATR)
- TDG 26.32
- BEATW 0.00
- MACD
- TDG 2.59
- BEATW 0.00
- Stochastic Oscillator
- TDG 76.81
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.